Paris, France et Londres, Royaume-Uni (30 mai 2025) – EssilorLuxottica et MidEuropa annoncent aujourd’hui avoir conclu un accord prévoyant l’acquisition d’Optegra par EssilorLuxottica. Optegra est une ...

Paris, France and London, United Kingdom (30 May 2025) – EssilorLuxottica and MidEuropa announced today they entered into an agreement for EssilorLuxottica to acquire Optegra, a fast-growing and ...

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Singapore, May 29, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today reaffirmed the strength of its underlying financial performance and strategic outlook, ...

SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April ...

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Live webcasts of the fireside chats will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcasts will be archived on ...

MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting ...

Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical ...

Poster Presentation: Pociredir, a Potent and Selective EED Inhibitor for the Treatment of Sickle Cell Disease, Induces Target Engagement and Gene Expression Changes that are Specific and Reversible in ...